Finance

Lists
4559:TYO
Zeria Pharmaceutical Co Ltd
1 914,00 JP¥
+0,58%
(+11,00) 1D
6-окт., 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4559...
Open
1 903 JP¥
High
1 919 JP¥
Low
1 900 JP¥
Mkt. cap
95,93 млд
Avg. vol.
169,91 миң
Volume
137,50 миң
Dividend
2,56%
Quarterly dividend
12 JP¥
Ex-dividend date
2026-ж., 29-сен.
P/E ratio
10,25
52-wk high
2 434 JP¥
52-wk low
1 878 JP¥
EPS
187 JP¥
Shares outstanding
50,11 млн
No. of employees
2 миң
Open
1 903 JP¥
High
1 919 JP¥
Low
1 900 JP¥
Mkt. cap
95,93 млд
Avg. vol.
169,91 миң
Volume
137,50 миң
Dividend
2,56%
Quarterly dividend
12 JP¥
Ex-dividend date
2026-ж., 29-сен.
P/E ratio
10,25
52-wk high
2 434 JP¥
52-wk low
1 878 JP¥
EPS
187 JP¥
Shares outstanding
50,11 млн
No. of employees
2 миң
News stories
From web sources and news partners
Profile
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG. In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK. In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988. In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries, It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma. The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries. The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
About Zeria Pharmaceutical Co Ltd
CEOSachiaki Ibe
Employees1,75 миң
Founded1955-ж., 22-дек.
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
20,47 млд
24,12 млд
25,08 млд
21,45 млд
Cost of goods sold
5,59 млд
6,38 млд
6,43 млд
6,22 млд
Cost of revenue
5,59 млд
6,38 млд
6,43 млд
6,22 млд
Research and development expenses
-
-
3,71 млд
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
12,76 млд
12,82 млд
4,85 млд
13,28 млд
Operating expense
12,76 млд
12,82 млд
14,84 млд
13,28 млд
Total operating expenses
18,35 млд
19,19 млд
21,27 млд
19,50 млд
Operating income
2,12 млд
4,93 млд
3,81 млд
1,95 млд
Other non operating income
-23,00 млн
-81,04 млн
305,04 млн
-47,28 млн
EBT including unusual items
994,00 млн
4,63 млд
3,92 млд
1,43 млд
EBT excluding unusual items
994,00 млн
4,63 млд
3,76 млд
1,43 млд
Income tax expense
383,00 млн
795,44 млн
979,56 млн
547,57 млн
Effective tax rate
38,53%
-
25,02%
38,21%
Other operating expenses
-
-
-
-
Net income
647,00 млн
3,82 млд
2,90 млд
866,20 млн
Net profit margin
3,16%
-
11,56%
4,04%
Earnings per share
-
-
-
-
Interest and investment income
30,00 млн
136,71 млн
32,29 млн
305,03 млн
Interest expense
-119,00 млн
-123,00 млн
-138,00 млн
-132,04 млн
Net interest expenses
-89,00 млн
13,71 млн
-105,71 млн
172,99 млн
Depreciation and amortization charges
-
-
5,78 млд
-
EBITDA
3,88 млд
6,81 млд
5,65 млд
4,24 млд
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору